Possible Settlement Amounts for an Elmiron Lawsuit

Event News

Researcher: Ariana Arce​

Researcher: Ariana Arce​

a.arce@legalhelpadvisor.com

Journalist: Aaron Vivanco

Journalist: Aaron Vivanco

a.vivanco@legalhelpadvisor.com

Editor: Daniela Polo

Editor: Daniela Polo

d.polo@legalhelpadvisor.com

Contact Us

We will review your case so that we can help you become a part of the lawsuit to hold the company accountable.

Possible Settlement Amounts for an Elmiron Lawsuit

Elmiron is a Food and Drug Administration (FDA)-approved medication for interstitial cystitis since 1996 and has been commonly utilized as a safe and effective treatment option. However, recent concerns have emerged regarding its potential to cause severe eye damage, specifically maculopathy, a degenerative retinal disease that can result in vision loss.

Numerous individuals who have taken Elmiron and experienced vision issues have initiated legal actions against Janssen Pharmaceuticals Inc., the drug manufacturer, claiming that the company did not adequately disclose the potential risks of eye damage.

In 2020, multidistrict litigation (MDL) was established in the US District Court of New Jersey. The MDL formation begins the litigation process and enables the gathering of facts, trials, and eventual settlement discussions.

Elmiron effectiveness with bladder pain

Elmiron (pentosan polysulfate sodium) has been prescribed by doctors since 1996 to treat bladder and pelvic pain associated with interstitial cystitis, a condition that affects millions of Americans. Its typical dosage is three 100-mg doses per day for a minimum of 1 month, although some individuals may not experience improvement until 6 to 9 months of treatment. Patients commonly continue using Elmiron for extended periods, sometimes spanning years, or even decades.

Elmiron is produced by Janssen Pharmaceuticals. Research has indicated that patients taking Elmiron, especially in higher doses, have a heightened chance of developing maculopathy, a progressive eye condition that may result in loss of vision. Although maculopathy cannot be reversed, it can potentially be controlled with early identification and treatment.

Known side effects related to the use of Elmiron

Reports have associated the use of Elmiron with various side effects, including vision impairment, vision loss, blurred vision, macular degeneration, retinal disease, and other vision-related injuries, which were not listed on the drug’s label. As a result, vision damage lawsuits have been filed on Elmiron use.

Janssen Pharmaceuticals lists the following common Elmiron side effects:

  • Hair loss
  • Diarrhea
  • Nausea
  • Bloody stool
  • Headache
  • Rashes
  • Upset stomach
  • Abnormal liver functions
  • Dizziness
  • Bruising
  • Weight gain
  • Swelling

The FDA encourages healthcare professionals and patients to report any adverse reactions and side effects of Elmiron to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program for better safety monitoring.

Elmiron can cause maculopathy

Several post-marketing studies have established a connection between long-term Elmiron use and a severe eye condition known as retinal maculopathy. Maculopathy is a disease that progresses over time and can lead to vision problems, including central vision loss, and potential blindness.

The form of macular degeneration associated with Elmiron is known as “pigmentary maculopathy.” Maculopathy refers to damage to the macula, located at the back of the eye. Individuals with macular damage may experience various visual symptoms, such as diminished, or blurred vision, image distortion, central vision spots, and legal blindness.

What is the status of the settlement for the Elmiron MDL?

There is significant scientific evidence that connects Elmiron to a distinct form of vision damage. Previous cases involving hazardous drugs have resulted in significant settlements based on medical evidence that may be considered less compelling. Despite the absence of certainties in litigation, we anticipate that substantial settlement amounts may be offered to Elmiron victims.

The Elmiron class-action MDL will likely result in a settlement. The settlement details, including the amount and arrangement, are still uncertain.

Structured payouts are typically used in mass tort cases to determine compensation amounts in a tier system based on a point system. Considering an Elmiron settlement in tiers can provide a useful framework for understanding potential compensation payouts.

Elmiron lawsuits are categorized into tiers based on the severity of the plaintiff’s injuries, with higher tiers receiving higher settlement payouts and lower tiers receiving lower payouts.

For example, a plaintiff who is completely blind would be categorized in the highest tier, whereas a plaintiff with partial vision impairment would be categorized in the lowest tier.

What is the average payout for an Elmiron MDL?

The Elmiron litigation is still at its early stage, making it difficult for lawyers to accurately predict the settlement amounts. However, an estimation can be made by comparing the settlement amounts of similar cases with similar injuries.

The victims involved in Elmiron lawsuits commonly experience vision impairment, macular degeneration, and vision as their injuries. The payout for vision loss or impairment injuries in other cases can be used as a reference for financial compensation in Elmiron cases.

How long will it take before you get a settlement for your eye damage lawsuit?

The duration of your Elmiron potential claim may vary depending on several factors, such as your inclusion in the MDL, the outcomes of bellwether cases, and any settlement offers made by Elmiron.

The Elmiron action may be fast-tracked due to strong scientific evidence against the drug.

The statute of limitations to file an Elmiron lawsuit is typically short, generally only a year, or two in most states. It is advised to promptly seek legal counsel if you have experienced vision problems after taking Elmiron.

Requirements to file an Elmiron lawsuit?

Patients diagnosed with eye problems after using Elmiron for a minimum of 2 years might qualify to file an Elmiron lawsuit. Lawyers will consider additional criteria that could impact eligibility.

You may qualify to file an Elmiron lawsuit if you:

  • Took Elmiron for at least 2 years.
  • Sought medical treatment for vision issues.
  • Suffered visual changes such as blurry vision, difficulty reading, distorted vision, eye pain, retinal damage, issues adjusting to the darkness, vision disturbances, or permanent vision loss after taking Elmiron.
  • Were diagnosed with vision problems or started having vision problems while taking the medication or within 1 year of stopping the medication.

Consulting with a lawyer is necessary to determine your eligibility for filing an Elmiron lawsuit. If you have any doubts about meeting the criteria mentioned, it is advisable to contact an Elmiron lawyer. By answering a few questions, our legal team can determine your eligibility, without charge for the consultation.